Jubilant Pharmova Limited(NSE:JUBLPHARMA)

Jubilant Pharmova Ltd. engages in the provision of basic organic chemicals. It operates through the following segments: Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation, Generics, and Proprietary Novel Drugs. The Radiopharma segment is involved in products for diagnosis and treatment of various diseases, including Pulmonary Embolism, Cancer, Coronary Artery Diseaseand many others. The Allergy Immunotherapy segment provides diagnostic devices for skin testing. The CDMO Sterile Injectables segment offer manufacturing services including sterile fill and finish injectables, full-service ophthalmic offer, and ampoules. The Generics segment includes development, manufacturing, distribution, sales and marketing of generics formulations. The CRDMO segment relates to drug discovery and development services. The company was founded on June 21, 1978 and is headquartered in Noida, India.